Contrasting Interpace Diagnostics Group (NASDAQ:IDXG) and Cytocore (NASDAQ:MDIT)

Interpace Diagnostics Group (NASDAQ:IDXG) and Cytocore (OTCMKTS:MDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Profitability

This table compares Interpace Diagnostics Group and Cytocore’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Interpace Diagnostics Group -65.86% -42.91% -28.66%
Cytocore N/A N/A N/A

Volatility & Risk

Interpace Diagnostics Group has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500. Comparatively, Cytocore has a beta of 3.67, indicating that its stock price is 267% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Interpace Diagnostics Group and Cytocore, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Interpace Diagnostics Group 0 0 3 0 3.00
Cytocore 0 0 0 0 N/A

Interpace Diagnostics Group presently has a consensus target price of $3.00, indicating a potential upside of 284.62%. Given Interpace Diagnostics Group’s higher probable upside, equities research analysts clearly believe Interpace Diagnostics Group is more favorable than Cytocore.

Institutional & Insider Ownership

19.0% of Interpace Diagnostics Group shares are owned by institutional investors. 18.8% of Interpace Diagnostics Group shares are owned by company insiders. Comparatively, 85.4% of Cytocore shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Interpace Diagnostics Group and Cytocore’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Interpace Diagnostics Group $21.90 million 1.36 -$12.19 million ($0.43) -1.81
Cytocore $6.81 million 0.87 -$6.81 million N/A N/A

Cytocore has lower revenue, but higher earnings than Interpace Diagnostics Group.

Summary

Cytocore beats Interpace Diagnostics Group on 6 of the 11 factors compared between the two stocks.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Cytocore Company Profile

MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.